38049923|t|Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.
38049923|a|BACKGROUND: Cognitive decline in Alzheimer's disease (AD) is associated with hyperphosphorylated tau (pTau) propagation between neurons along synaptically connected networks, in part via extracellular vesicles (EVs). EV biogenesis is triggered by ceramide enrichment at the plasma membrane from neutral sphingomyelinase2 (nSMase2)-mediated cleavage of sphingomyelin. We report, for the first time, that human tau expression elevates brain ceramides and nSMase2 activity. METHODS: To determine the therapeutic benefit of inhibiting this elevation, we evaluated PDDC, the first potent, selective, orally bioavailable, and brain-penetrable nSMase2 inhibitor in the transgenic PS19 AD mouse model. Additionally, we directly evaluated the effect of PDDC on tau propagation in a mouse model where an adeno-associated virus (AAV) encoding P301L/S320F double mutant human tau was stereotaxically-injected unilaterally into the hippocampus. The contralateral transfer of the double mutant human tau to the dentate gyrus was monitored. We examined ceramide levels, histopathological changes, and pTau content within EVs isolated from the mouse plasma. RESULTS: Similar to human AD, the PS19 mice exhibited increased brain ceramide levels and nSMase2 activity; both were completely normalized by PDDC treatment. The PS19 mice also exhibited elevated tau immunostaining, thinning of hippocampal neuronal cell layers, increased mossy fiber synaptophysin immunostaining, and glial activation, all of which were pathologic features of human AD. PDDC treatment reduced these changes. The plasma of PDDC-treated PS19 mice had reduced levels of neuronal- and microglial-derived EVs, the former carrying lower pTau levels, compared to untreated mice. In the tau propagation model, PDDC normalized the tau-induced increase in brain ceramides and significantly reduced the amount of tau propagation to the contralateral side. CONCLUSIONS: PDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice.
38049923	11	14	tau	Gene	4137
38049923	32	39	nSMase2	Gene	58994
38049923	53	62	ceramides	Chemical	MESH:D002518
38049923	84	103	Alzheimer's disease	Disease	MESH:D000544
38049923	129	146	Cognitive decline	Disease	MESH:D003072
38049923	150	169	Alzheimer's disease	Disease	MESH:D000544
38049923	171	173	AD	Disease	MESH:D000544
38049923	214	217	tau	Gene	4137
38049923	219	223	pTau	Chemical	-
38049923	364	372	ceramide	Chemical	MESH:D002518
38049923	412	437	neutral sphingomyelinase2	Gene	58994
38049923	439	446	nSMase2	Gene	58994
38049923	469	482	sphingomyelin	Chemical	MESH:D013109
38049923	526	529	tau	Gene	4137
38049923	556	565	ceramides	Chemical	MESH:D002518
38049923	570	577	nSMase2	Gene	58994
38049923	677	681	PDDC	Chemical	MESH:C044858
38049923	754	761	nSMase2	Gene	58994
38049923	795	797	AD	Disease	MESH:D000544
38049923	861	865	PDDC	Chemical	MESH:C044858
38049923	869	872	tau	Gene	4137
38049923	949	954	P301L	ProteinMutation	tmVar:p|SUB|P|301|L;HGVS:p.P301L;VariantGroup:1;CorrespondingGene:4137;RS#:63751273;CorrespondingSpecies:9606;CA#:225444
38049923	955	960	S320F	ProteinMutation	tmVar:p|SUB|S|320|F;HGVS:p.S320F;VariantGroup:0;CorrespondingGene:4137;RS#:63750635;CorrespondingSpecies:9606;CA#:225475
38049923	981	984	tau	Gene	4137
38049923	1103	1106	tau	Gene	4137
38049923	1155	1163	ceramide	Chemical	MESH:D002518
38049923	1203	1207	pTau	Chemical	-
38049923	1285	1287	AD	Disease	MESH:D000544
38049923	1329	1337	ceramide	Chemical	MESH:D002518
38049923	1349	1356	nSMase2	Gene	58994
38049923	1402	1406	PDDC	Chemical	MESH:C044858
38049923	1456	1459	tau	Gene	4137
38049923	1544	1557	synaptophysin	Gene	20977
38049923	1643	1645	AD	Disease	MESH:D000544
38049923	1647	1651	PDDC	Chemical	MESH:C044858
38049923	1699	1703	PDDC	Chemical	MESH:C044858
38049923	1808	1812	pTau	Chemical	-
38049923	1856	1859	tau	Gene	4137
38049923	1879	1883	PDDC	Chemical	MESH:C044858
38049923	1899	1902	tau	Gene	4137
38049923	1929	1938	ceramides	Chemical	MESH:D002518
38049923	1979	1982	tau	Gene	4137
38049923	2035	2039	PDDC	Chemical	MESH:C044858
38049923	2113	2122	ceramides	Chemical	MESH:D002518
38049923	2127	2134	nSMase2	Gene	58994
38049923	2171	2174	tau	Gene	4137
38049923	2185	2187	AD	Disease	MESH:D000544
38049923	Association	RS#:63750635;HGVS:p.S320F;CorrespondingGene:4137	RS#:63751273;HGVS:p.P301L;CorrespondingGene:4137
38049923	Association	MESH:D013109	58994
38049923	Association	MESH:D000544	RS#:63751273;HGVS:p.P301L;CorrespondingGene:4137
38049923	Negative_Correlation	MESH:C044858	58994
38049923	Association	MESH:D002518	58994
38049923	Negative_Correlation	MESH:C044858	MESH:D002518
38049923	Positive_Correlation	4137	58994
38049923	Negative_Correlation	MESH:C044858	4137
38049923	Association	MESH:D002518	MESH:D000544
38049923	Positive_Correlation	MESH:D002518	4137
38049923	Association	MESH:D003072	4137
38049923	Negative_Correlation	MESH:C044858	MESH:D000544
38049923	Negative_Correlation	MESH:C044858	20977
38049923	Association	MESH:D000544	4137
38049923	Association	MESH:D000544	58994

